TikTok is saturated with stories of people gaining weight back after their final shot and entering another weight loss cycle
This article summarises the position reached with the GLP-1 RAs and reviews the developing field of unimolecular co-agonists that act not only on the GLP-1 receptor, but on other receptors, notably glucose-dependent insulotropic polypeptide (GIP) and glucagon receptors, with the aim of further improving glycaemic control and weight reduction
That we may need higher level interventions to really turn that around so that those diet and lifestyle efforts can have a greater impact, which is what you said at the top of this, but I want to remind people of that because I think when we have these conversations about these medications, there's, it falls into two camps, like the people who are like, give it to everyone, it saves that, like all of these things, all these wonderful things
First, GI adverse effects were numerically more common with CagriSema (58Percentage) compared with semaglutide (32Percentage) or cagrilintide (32Percentage) [10]
In patients with a high risk of cancers where GLP1R expression is associated with poor outcomes, alternative therapies might be more appropriate